Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Impedimed Limited ( (AU:IPD) ).
ImpediMed Limited has released an investor presentation outlining its Q2 FY26 results, which will be delivered to investors and analysts, signalling ongoing engagement with the market about its financial and operational performance. While specific figures are not disclosed in the release, the scheduled presentation underscores the company’s efforts to maintain transparency with stakeholders and could shape investor perceptions of its near-term outlook and strategic progress.
The most recent analyst rating on (AU:IPD) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited is an Australian medical technology company listed on the ASX that develops and commercialises bioimpedance-based devices and software, with a focus on clinical applications such as fluid status and body composition assessment for healthcare providers and patients.
Average Trading Volume: 1,505,358
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$67.28M
See more insights into IPD stock on TipRanks’ Stock Analysis page.